Corautus Suspends Clinical Trial, Cancels Public Offering
Corautus shares fell 15 percent to close at $3.40 Tuesday on the news. Corautus had planned to raise $26.5 million through the stock offering.
Corautus said it was suspending the trial at the request of Boston Scientific. Corautus was using a catheter system from Boston Scientific to deliver its investigational treatment for angina. Boston Scientific made the request after three reports of "serious adverse events" which don't appear to be related to the drug, Corautus said in a statement.
Corautus: www.corautus.comCopyright 2013 by Capitol Broadcasting Company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Log in or upgrade to view WRALTechWire Insider content
Please Log In to add a comment.